Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 25, 2025 07:30 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Provides Shareholder Update

Propanc is entering a transformational stage as it prepares for the advancement of its lead asset, “PRP”, to enter a Phase 1B, First-In-Human (FIH) study
August 19, 2025 08:30 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Propanc Biopharma closes an underwritten public offering of 1,000,000 shares of its common stock at a price of $4.00 per share
August 14, 2025 23:00 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Propanc completes pricing of an underwritten public offering of 1,000,000 shares of its common stock at a price of $4.00 per share